Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax extension study for participants completing a prior venetoclax trial
2022-501522-38-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, open-label trial of venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), non-Hodgkin lymphoma (NHL), multiple myeloma (MM) and 2 more (2 arms), sponsored by AbbVie Inc. Primary endpoint: Adverse event collection. Planned start Sep 2020; status: authorised.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)non-Hodgkin lymphoma (NHL)multiple myeloma (MM)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2022-501522-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501522-38-00.